Expert Perspectives on Fixed Duration Therapy with Venetoclax + Obinutuzumab

Opinion
Video

A panel of experts discuss the role of fixed duration therapy with venetoclax and obinutuzumab, outlining their general approach for patient selection.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.